1 / 62

The Treatment of Mood and Anxiety Disorders in HIV

The Treatment of Mood and Anxiety Disorders in HIV. Marshall Forstein, MD Associate Professor of Psychiatry Harvard Medical School Chair, Steering Committee on HIV Psychiatry American Psychiatric Association. Disclosures. Nothing to disclose.

viveca
Download Presentation

The Treatment of Mood and Anxiety Disorders in HIV

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Treatment of Mood and Anxiety Disorders in HIV Marshall Forstein, MD Associate Professor of Psychiatry Harvard Medical School Chair, Steering Committee on HIV Psychiatry American Psychiatric Association

  2. Disclosures • Nothing to disclose

  3. Mood Disorder due to a General Medical Condition Substance-Induced Mood Disorder Major Depression Demoralization Adjustment Disorder • Grief • Sadness • Disillusionment • Despondency Dysthymia “Depressive Personality” “Minor Depression” Sub-syndromal Major Depression

  4. Mood Disorders • Mood disorders are the most frequent psychiatric complication associated with HIV disease • Mood disorders may be more prevalent in people at risk for HIV infection • Mood disorders may be secondary to HIV complications or its treatment

  5. Prevalence of Axis I Disorders in Multi-site HIV/AIDS Mental Health Demonstration Project Major Depression 60% Substance Use Disorders 50% Dysthymic Disorder 25% Anxiety Disorders 25% McDaniel et al., 1999

  6. Impact of depression • Depression causes biologic changes in endocrine and immune function that may contribute to disease progression and mortality • Impacts readiness for ART and adherence with treatment

  7. DSM IV Depressive Disorders • Major depression (can include psychotic features) • Dysthymia ( long standing low mood) • Bipolar depression ( manic-depression) • Type I, Type II • Substance induced mood disorders • Mood disorder due to general medical condition • Cyclothymia ( frequent ups and downs)

  8. Differential Diagnosis • Mood disorder due to a general medical condition: Diabetes, cardiac disease • CNS HIV cognitive disorders • CNS opportunistic illnesses and cancers • Medication effects • Other medical & endocrine abnormalities

  9. Impact of depression in HIV • Depressive symptoms and psychological stress associated with: • More rapid progression of illness • Higher mortality rates • Poor adherence with treatment • Increased risk for secondary transmission • Greater impairments in psychosocial function

  10. Depression as AIDS Develops 20 PERCENT DEPRESSED 10 TIME OF AIDS Lyketsos et. al., 1995 0 -48 -36 -24 -12 6 18 MONTHS BEFORE AND AFTER AIDS

  11. Prevalence of Depression • Epidemiologic study of 2864 HIV + • Almost 50% identified as having a psychiatric disorder • >1/3 were positive for major depression • >1/4 were positive for dysthymia Bing EG, Burnam MA, Longshore D, et al.: Psychiatric disorders and drug use among human immunodefi ciency virus-infected adults in the United States. Arch Gen Psychiatry 2001, 58:721–728.

  12. HIV+ women and depression • May be more vulnerable than men as in the general population • Study of 765 HIV + women • 42% had chronic depressive symptoms • 35% had intermittent depressive symptoms • HIV+ women 4x more likely to be depressed than HIV- women [Morrison et al ]

  13. Kaiser Permanente and Group Health Cooperative • 42 % had a depression diagnosis • only 15 % used SSRIs. • Depression without SSRI use significantly decreased the odds of achieving 90 percent or greater adherence to ART • Risk for mutation and secondary transmission of resistant virus

  14. AFFECTIVE Depressed mood Loss of interest Guilt, worthlessness Hopelessness Suicidal ideation SOMATIC Appetite/Weight loss Sleep disturbance Agitation/retardation Fatigue Loss of concentration Affective vs. Somatic Symptoms: Depressive Symptoms

  15. Treatment of Depression • Antidepressant Agents • No one drug has clear superiority over others • Chosen on the basis of • Side effect profile • Drug-drug interaction

  16. Other treatments for mood disorders • Testosterone • Evidence for improvement of mood in hypogonadism • Psychostimulants • Methylphenidate • Dextroamphetamine • Modafinil

  17. Psychotherapy for depression • Best evidence is for combination of CBT and medication • Few randomized studies • Interpersonal psychotherapy (IPT) • New evidence based meta-analysis of dynamic therapies • Group , psycho educational or therapeutic

  18. Rule out medical co-morbidity • Hepatitis C infection (independent of HIV coinfection and interferon/ribavirin therapy) ) • Fatigue 97% of patients • Depression 25 % current • Up to 70% have elevated scores on depression rating scales • cognitive dysfunction • (up to 82% impairment on some measures). Crone C, Gabriel GM: Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment and interferon-based therapy complications. J PsychiatrPract 2003, 9:93–110.

  19. Depression and adherence • Depression is an independent predictor of adherence and mortality in women. • Antiretroviral adherence did not predict antidepressant adherence • antidepressant adherence did predict antiretroviral adherence • Villes V et al, The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice. AntivirTher 2007; 12(7): 1067-74. ; • Lima VD, et al, The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS, 2007 May 31; 21(9): 1175-83 • Bottonari KA, Tripathi, SP, Fortney JC, Rimland D, Rodriguez-Barradas M, Gifford AL, Pyne JA, Correlates of Antiretroviral and Antidepressant Adherence Among Depressed HIV-Infected Patients, AIDS PATIENT CARE and STDs Volume 26, Number 5, 2012

  20. Endocrine dysfunction and mental dysfunction • Clinical and subclinical hypothyroidism • 16% prevalence • Beltran S, Lescure F-X, Desailloud R, et al.: Increased prevalence of hypothyroidism among human immunodeficiency virus infected patients: a need for screening. Clin Infect Dis 2003, 37:579–583. • Hypogonadism • Up to 50% in symptomatic HIV • Mylonakis E, Koutkia P, Grinspoon S: Diagnosis and treatment of androgen deficiency in human immunodeficiencyvirus-infected men and women. Clin Infect Dis 2001, 33:857–864.

  21. Rule out medical co-morbidity • Hepatitis C infection (independent of HIV coinfection and interferon/ribavirin therapy) ) • Fatigue 97% of patients • Depression 25 % current • Up to 70% have elevated scores on depression rating scales • cognitive dysfunction • (up to 82% impairment on some measures). Crone C, Gabriel GM: Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment and interferon-based therapy complications. J PsychiatrPract 2003, 9:93–110.

  22. Endocrine dysfunction and mental dysfunction • Clinical and subclinical hypothyroidism • 16% prevalence • Beltran S, Lescure F-X, Desailloud R, et al.: Increased prevalence of hypothyroidism among human immunodeficiency virus infected patients: a need for screening. Clin Infect Dis 2003, 37:579–583. • Hypogonadism • Up to 50% in symptomatic HIV • Mylonakis E, Koutkia P, Grinspoon S: Diagnosis and treatment of androgen deficiency in human immunodeficiencyvirus-infected men and women. Clin Infect Dis 2001, 33:857–864.

  23. Endocrine dysfunction and mental dysfunction • Adrenal insufficiency • 50% in severely ill HIV • Mayo J, Callazos J, Martinez E, Ibarra S: Adrenal function in the human immunodeficiency virus-infected patient. Arch Intern Med 2002, 162:1095–1098. • Graves disease • Chen F, Day SL, Metcalfe RA, et al.: Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine (Baltimore) 2005, 84:98–106.

  24. Endocrine dysfunction and mental dysfunction • Adrenal insufficiency • 50% in severely ill HIV • Mayo J, Callazos J, Martinez E, Ibarra S: Adrenal function in the human immunodeficiency virus-infected patient. Arch Intern Med 2002, 162:1095–1098. • Graves disease • Chen F, Day SL, Metcalfe RA, et al.: Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine (Baltimore) 2005, 84:98–106.

  25. Symptoms of Endocrine Dysfunction • Fatigue, low mood, low libido, and loss of lean body mass • Acute-stage Graves’ disease presents with activation symptoms such as anxiety, irritability, insomnia, weight loss, mania, and agitation. • symptoms may be ameliorated by correction of the deficiency state.

  26. Confounding Dx’s • Increasing prevalence of neurocognitive disorders • CNS inflammation in both Primary HIV neurocognitive disorders and depression • Co- occurring HCV • Substance use • Especially Methamphetamine- neurotoxic

  27. Anxiety and HIV • Importance of identifying anxiety • evidence linking these disorders to both high-risk behaviors and antiretroviral non-adherence. • Hilerio CM, Martínez J, Zorrilla CD, et al. Posttraumatic stress disorder symptoms and adherence among women living with HIV. Ethn Dis. 2005;15(4 Suppl 5):S5-47-S5-50.   • Roux P, Carrieri MP, Michel L, et al. Effect of anxiety symptoms on adherence to highly active antiretroviral therapy in HIV-infected women. J Clin Psychiatry. 2009;70:1328-1329.

  28. A diagnosis of an anxiety disorder is a diagnosis of exclusion • Anxiety symptoms (Somatic complaints) • shortness of breath, • chest pain, • racing/pounding heart, • dizziness, • diaphoresis, (sweatiness) • numbness or tingling, • nausea, • sensation of choking

  29. A diagnosis of an anxiety disorder is a diagnosis of exclusion • Anxiety symptoms (psychological) • fear, worry, • insomnia, • impaired concentration and memory, • diminished appetite, • ruminations, • compulsive rituals, • avoidance of situations that make them anxious.

  30. Anxiety Sensitivity (AS) • AS is operationally defined as the fear of anxiety and arousal-related sensations. McNally RJ. Anxiety sensitivity and panic disorder. BiolPsychiatry 2002;52:938–946

  31. Anxiety Sensitivity • conceptualized as a relatively stable cognitive factor that is conceptually and empirically distinct from the actual experience of (negative) emotional states. Bernstein A, Zvolensky MJ. Anxiety sensitivity: Selective review of promising research and future directions. Expert Rev Neurother 2007;7:97–101.

  32. Anxiety Sensitivity • AS is incrementally related to greater anxiety, somatization, and depression symptoms among persons with HIV/AIDS Gonzalez A, Zvolensky MJ, Solomon SE, Miller CT. Exploration of the relevance of anxiety sensitivity among adults living with HIV/AIDS for understanding anxiety vulnerability. J Health Psychol 2010;15:138–146.

  33. Anxiety Sensitivity • When anxious or experiencing somatic symptoms, individuals high in AS may become more acutely fearful due, specifically, to beliefs that these anxiety and related bodily sensations (e.g., rapid heartbeat) have harmful personal consequences (e.g.,‘‘I am going crazy’’).

  34. Symptom Distress and AS: interactive model of anxiety • HIV symptom distress and AS may interact to confer greater risk for anxiety symptoms. • higher levels of HIV symptom distress may be exacerbated by an individual’s level of AS, and thereby may be associated with higher anxiety symptoms • individual’s HIV symptom distress level may trigger more AS-specific cognitive reactions

  35. The following questions may help determine if anxiety is present • Are you anxious? • Are you fearful or afraid? • Do you worry a lot? • Are you tense or irritable? • Are you restless? • Do you have difficulty sleeping?

  36. Anxiety in HIV+ • Anxiety symptoms are commonly experienced during periods of illness and may be a response to stressful situations.

  37. Anxiety Disorder Present if Symptoms: • Interfere with a patient’s daily function (e.g., the patient is unable to work, leave home, attend to medical care) • Interfere with personal relationships • Cause marked subjective distress

  38. Anxiety Disorders in HIV + people in medical care • Anxiety disorder 20.3% • Panic disorder 12.3 % • PTSD 10.4 % • GAD 2.8 % VitielloB, Burnam MA, Bing EG, et al. Use of psychotropic medications among HIV-infected patients in the United States. Am J Psychiatry,2003;160:547-554.

  39. Underlying medical conditions may also cause anxiety symptoms: • CNS pathologies: HIV-related infections, neoplasms, dementia, or delirium • Systemic or metabolic illness: hypoxia, sepsis, electrolyte imbalance • Endocrinopathies: thyroid disease, hypoglycemia, pheochromocytoma, Cushing’s syndrome

  40. Underlying medical conditions may also cause anxiety symptoms: • Respiratory conditions: pneumonia • Cardiovascular conditions: arrhythmias, pulmonary embolus • Substance intoxication/withdrawal: from alcohol, nicotine, caffeine, opiates, methadone, buprenorphine, cocaine, and amphetamines

  41. Management of Anxiety Disorders • Referral to Mental Health Provider for Diagnosis and Treatment when: • Mild anxiety symptoms do not respond to psychosocial interventions in the primary care setting • Anxiety symptoms are persistent or severe • Intrusive or disturbing obsessive thoughts or compulsive rituals are present • Anxiety symptoms are occurring in patients with a current or past history of substance use disorders

  42. Psychosocial Intervention for Mild Anxiety Symptoms in the Primary Care Setting • Express empathy • Educate patients about anxiety • Identify the psychosocial factors that contribute to patients’ anxiety symptoms, including financial and housing instability, social isolation, and conflict in key relationships, and refer patients for supportive services

  43. Psychosocial Intervention for Mild Anxiety Symptoms in the Primary Care Setting • Prepare patients for stressful situations and assist in development of coping strategies and interventions • Counsel patients to reduce intake of anxiety-inducing substances such as caffeine and nicotine • Teach patients simple relaxation exercises. Slow, deep abdominal breathing can be useful when patients practice for 1 minute three times a day, increasing to 5 minutes, if possible

  44. Patients who do not respond to basic psychosocial interventions, and patients with more severe anxiety symptoms or a possible anxiety disorder, may require psychopharmacologic treatment and/or specialized psychotherapeutic treatment.

  45. Assessing Depression • PHQ-9

  46. PHQ-9 #10

  47. PHQ-9 — Nine Symptom Checklist 2) If you checked off any problem on this questionnaire so far, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people? • Not Difficult at All (0) • Somewhat Difficult (1) • Very Difficult (2) • Extremely Difficult (3)

More Related